自噬
ULK1
抗药性
癌症研究
癌变
药品
激酶
癌症
医学
生物
药理学
蛋白激酶A
细胞生物学
生物化学
内科学
遗传学
安普克
细胞凋亡
作者
Li Liu,Lu Yan,Ning Liao,Wan-Qin Wu,Junling Shi
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2020-02-04
卷期号:12 (2): 352-352
被引量:90
标识
DOI:10.3390/cancers12020352
摘要
The difficulty of early diagnosis and the development of drug resistance are two major barriers to the successful treatment of cancer. Autophagy plays a crucial role in several cellular functions, and its dysregulation is associated with both tumorigenesis and drug resistance. Unc-51-like kinase 1 (ULK1) is a serine/threonine kinase that participates in the initiation of autophagy. Many studies have indicated that compounds that directly or indirectly target ULK1 could be used for tumor therapy. However, reports of the therapeutic effects of these compounds have come to conflicting conclusions. In this work, we reviewed recent studies related to the effects of ULK1 on the regulation of autophagy and the development of drug resistance in cancers, with the aim of clarifying the mechanistic underpinnings of this therapeutic target.
科研通智能强力驱动
Strongly Powered by AbleSci AI